X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device

Yuvraj_pawp by Yuvraj_pawp
10th July 2014
in FDA Approvals

One Spray per Device, Without the Need for Priming, Provides Greater Ease of Use

 

Strativa Pharmaceuticals, the branded division of Par Pharmaceutical Companies, Inc., today announced that the U.S. Food and Drug Administration has approved Nascobal® Nasal Spray in a single-use device. Nascobal® is a prescription vitamin B12 supplement administered as one spray, one nostril, once a week. Each single-use device delivers one spray of 500 mcg of cyanocobalamin, USP. Unlike the current multi-use glass bottle with actuator pump, no priming is required with the new single-use device, which delivers a precise dose upon administration. A carton of four single-use devices provides patients with a convenient one month supply of Nascobal®. Nascobal® Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement. Nascobal® Nasal Spray is also indicated as a supplement for other vitamin B12 deficiencies.

 

“Unlike the current device, our new Nascobal® single-use device does not require priming, which eliminates product loss. In addition, it permits patients to conveniently receive their dose with one spray per disposable device,” said Rick Painter, Senior Vice President, Brand Sales and Marketing. “Strativa remains committed to improving the product experience of the patients who rely upon us,” Mr. Painter said.

 

The new Nascobal® Nasal Spray single-use device requires no assembly and simplifies the tracking of dose administration. The disposable single-use device is hygienic, portable and will replace the currently available multi-use product. It will be available in pharmacies in September. Strativa is continuing the development of new and enhanced versions of Nascobal® in order to better meet the needs of those patients who rely upon the product.

 

Important Information About Nascobal® Nasal Spray

 

Nascobal® Nasal Spray is contraindicated in patients with sensitivity to cobalt and/or vitamin B12 or any component of the medication. Patients with pernicious anemia should be instructed that they will require weekly administration of Nascobal® for the rest of their lives. If a patient is not properly maintained with Nascobal® Nasal Spray, intramuscular vitamin B12 is necessary. Vitamin B12 concentrations must be monitored. Patients with early Leber’s disease (hereditary optic nerve atrophy) who were treated with vitamin B12 suffered severe and swift optic nerve atrophy. Vitamin B12 deficiency may suppress signs of polycythemia vera. Treatment with vitamin B12 may mask this condition. Hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely with vitamin B12. Side effects thought to be related to Nascobal® are usually mild and include headache, nausea, and rhinitis.

 

About Par Pharmaceutical Companies, Inc.

 

Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.

 

About Strativa Pharmaceuticals

 

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc., excels at finding, enhancing and bringing to market drugs that make a meaningful difference to patients.

 

Tags: Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (CyanocobalaminUSP) Nasal Spray Single-Use Device
Previous Post

Glenmark Generics receives final ANDA approval for Telmisartan tablets

Next Post

Astellas Details Pipeline Progress at R&D Meeting

Related Posts

JSR Life Sciences Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy
FDA Approvals

JSR Life Sciences Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

22nd March 2022
Lynparza From AZ As Breast Cancer Cure Gets FDA Approval
FDA Approvals

Lynparza From AZ As Breast Cancer Cure Gets FDA Approval

15th March 2022
New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System
FDA Approvals

New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

31st January 2022
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
FDA Approvals

Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

29th January 2022
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
FDA Approvals

Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

29th January 2022
EC Approves Merck's KEYTRUDA as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
FDA Approvals

EC Approves Merck’s KEYTRUDA as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery

29th January 2022
Next Post

Astellas Details Pipeline Progress at R&D Meeting

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In